PNAS:艾滋病患者有救了,全新疗法彻底解决HIV病毒耐药问题!

2017-08-24 Lily 来宝网

根据南加州大学凯克医学院的研究员所述,将来的某一天,研究人员将对目前“鸡尾酒疗法”产生抗药性的HIV病毒感染者们使用全新的治疗方法,靶向人体内的蛋白质,而不是发生突变的病毒。



美国艾滋病研究者确定了治疗艾滋病的新方法】根据南加州大学凯克医学院的研究员所述,将来的某一天,研究人员将对目前“鸡尾酒疗法”产生抗药性的HIV病毒感染者们使用全新的治疗方法,靶向人体内的蛋白质,而不是发生突变的病毒。

为了在艾滋病治疗领域取得突破性进展,来自南加州大学的研究人员花了13年的时间,研究如何控制病毒感染人类免疫系统。最近,在实验室中发现了一个蛋白质变体,可以有针对性的预防人类免疫缺陷,使病毒伤害艾滋病病毒感染者。

研究人员表示,大多数艾滋病药物靶向病毒的分子微生物,但是病毒是不稳定的,因此可以逐渐对有效药物产生耐药性。在出版于《美国国家科学院学报》杂志的报告指出,靶向病毒的治疗方法总是会出现耐药性,但是如果靶向自身免疫系统的蛋白质,就可以从另一个角度对抗艾滋病。

研究人员表示,虽然我们还需要做更多的研究,但我们可以肯定的是,我们发现了治疗急性HIV感染的新方法。

全世界大约有3700万人感染了艾滋病毒,约2000万人正在接受抗病毒治疗,虽然,目前的疗法对大多数人效果都不错,但是不能忽视的问题是,有一部分艾滋病感染者确实开始出现耐药性,因此,作为研究人员必须提前做好准备工作,把这一问题的伤害降低到最低的程度。

原始出处:

Wan-Lin Wu et al. Δ20 IFITM2 differentially restricts X4 and R5 HIV-1, Proceedings of the National Academy of Sciences (2017). DOI: 10.1073/pnas.1619640114.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (15)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1799648, encodeId=70b81e9964853, content=<a href='/topic/show?id=49d4e0980cc' target=_blank style='color:#2F92EE;'>#病毒耐药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70980, encryptionId=49d4e0980cc, topicName=病毒耐药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4193478, createdName=wgx306, createdTime=Tue Jan 30 19:24:00 CST 2018, time=2018-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1856055, encodeId=8f591856055fc, content=<a href='/topic/show?id=f32014428fc' target=_blank style='color:#2F92EE;'>#PNAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14428, encryptionId=f32014428fc, topicName=PNAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Sat Jul 07 09:24:00 CST 2018, time=2018-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1807578, encodeId=9424180e578a8, content=<a href='/topic/show?id=ec2b80423ef' target=_blank style='color:#2F92EE;'>#耐药问题#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80423, encryptionId=ec2b80423ef, topicName=耐药问题)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Mon Jun 25 22:24:00 CST 2018, time=2018-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958060, encodeId=6e8b195806054, content=<a href='/topic/show?id=a2cd868009b' target=_blank style='color:#2F92EE;'>#艾滋病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86800, encryptionId=a2cd868009b, topicName=艾滋病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c83329, createdName=10518093zz, createdTime=Fri Oct 13 19:24:00 CST 2017, time=2017-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=243874, encodeId=38b62438e4a8, content=学习一下很不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/23/ac01daf0962458a9eb8c0b1e2f6ce5bc.jpg, createdBy=04b81710322, createdName=1771ae4158m, createdTime=Thu Sep 14 09:53:37 CST 2017, time=2017-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412632, encodeId=7aa114126327c, content=<a href='/topic/show?id=32ec89220b' target=_blank style='color:#2F92EE;'>#HIV病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8922, encryptionId=32ec89220b, topicName=HIV病毒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fa102876871, createdName=tigerlr99, createdTime=Sat Aug 26 11:24:00 CST 2017, time=2017-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554502, encodeId=ed1a155450278, content=<a href='/topic/show?id=74e458559f5' target=_blank style='color:#2F92EE;'>#新疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58559, encryptionId=74e458559f5, topicName=新疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d03114536414, createdName=kcb074, createdTime=Sat Aug 26 11:24:00 CST 2017, time=2017-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=237221, encodeId=1b2523e2213e, content=xxlxxxl, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Sat Aug 26 06:56:10 CST 2017, time=2017-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=236879, encodeId=31aa2368e9df, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Fri Aug 25 06:58:26 CST 2017, time=2017-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=236859, encodeId=52d023685943, content=值得推荐一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLBWOEtiahpXHGVdbFId5PLgK775YNA1ria3lM9KsJT6iczgIhov5sobd1Nr0raUBP58GkUDzvfDic9RCg/0, createdBy=0d021989245, createdName=189****1577, createdTime=Fri Aug 25 06:29:48 CST 2017, time=2017-08-25, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1799648, encodeId=70b81e9964853, content=<a href='/topic/show?id=49d4e0980cc' target=_blank style='color:#2F92EE;'>#病毒耐药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70980, encryptionId=49d4e0980cc, topicName=病毒耐药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4193478, createdName=wgx306, createdTime=Tue Jan 30 19:24:00 CST 2018, time=2018-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1856055, encodeId=8f591856055fc, content=<a href='/topic/show?id=f32014428fc' target=_blank style='color:#2F92EE;'>#PNAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14428, encryptionId=f32014428fc, topicName=PNAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Sat Jul 07 09:24:00 CST 2018, time=2018-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1807578, encodeId=9424180e578a8, content=<a href='/topic/show?id=ec2b80423ef' target=_blank style='color:#2F92EE;'>#耐药问题#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80423, encryptionId=ec2b80423ef, topicName=耐药问题)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Mon Jun 25 22:24:00 CST 2018, time=2018-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958060, encodeId=6e8b195806054, content=<a href='/topic/show?id=a2cd868009b' target=_blank style='color:#2F92EE;'>#艾滋病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86800, encryptionId=a2cd868009b, topicName=艾滋病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c83329, createdName=10518093zz, createdTime=Fri Oct 13 19:24:00 CST 2017, time=2017-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=243874, encodeId=38b62438e4a8, content=学习一下很不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/23/ac01daf0962458a9eb8c0b1e2f6ce5bc.jpg, createdBy=04b81710322, createdName=1771ae4158m, createdTime=Thu Sep 14 09:53:37 CST 2017, time=2017-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412632, encodeId=7aa114126327c, content=<a href='/topic/show?id=32ec89220b' target=_blank style='color:#2F92EE;'>#HIV病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8922, encryptionId=32ec89220b, topicName=HIV病毒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fa102876871, createdName=tigerlr99, createdTime=Sat Aug 26 11:24:00 CST 2017, time=2017-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554502, encodeId=ed1a155450278, content=<a href='/topic/show?id=74e458559f5' target=_blank style='color:#2F92EE;'>#新疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58559, encryptionId=74e458559f5, topicName=新疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d03114536414, createdName=kcb074, createdTime=Sat Aug 26 11:24:00 CST 2017, time=2017-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=237221, encodeId=1b2523e2213e, content=xxlxxxl, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Sat Aug 26 06:56:10 CST 2017, time=2017-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=236879, encodeId=31aa2368e9df, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Fri Aug 25 06:58:26 CST 2017, time=2017-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=236859, encodeId=52d023685943, content=值得推荐一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLBWOEtiahpXHGVdbFId5PLgK775YNA1ria3lM9KsJT6iczgIhov5sobd1Nr0raUBP58GkUDzvfDic9RCg/0, createdBy=0d021989245, createdName=189****1577, createdTime=Fri Aug 25 06:29:48 CST 2017, time=2017-08-25, status=1, ipAttribution=)]
    2018-07-07 drwjr
  3. [GetPortalCommentsPageByObjectIdResponse(id=1799648, encodeId=70b81e9964853, content=<a href='/topic/show?id=49d4e0980cc' target=_blank style='color:#2F92EE;'>#病毒耐药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70980, encryptionId=49d4e0980cc, topicName=病毒耐药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4193478, createdName=wgx306, createdTime=Tue Jan 30 19:24:00 CST 2018, time=2018-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1856055, encodeId=8f591856055fc, content=<a href='/topic/show?id=f32014428fc' target=_blank style='color:#2F92EE;'>#PNAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14428, encryptionId=f32014428fc, topicName=PNAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Sat Jul 07 09:24:00 CST 2018, time=2018-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1807578, encodeId=9424180e578a8, content=<a href='/topic/show?id=ec2b80423ef' target=_blank style='color:#2F92EE;'>#耐药问题#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80423, encryptionId=ec2b80423ef, topicName=耐药问题)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Mon Jun 25 22:24:00 CST 2018, time=2018-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958060, encodeId=6e8b195806054, content=<a href='/topic/show?id=a2cd868009b' target=_blank style='color:#2F92EE;'>#艾滋病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86800, encryptionId=a2cd868009b, topicName=艾滋病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c83329, createdName=10518093zz, createdTime=Fri Oct 13 19:24:00 CST 2017, time=2017-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=243874, encodeId=38b62438e4a8, content=学习一下很不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/23/ac01daf0962458a9eb8c0b1e2f6ce5bc.jpg, createdBy=04b81710322, createdName=1771ae4158m, createdTime=Thu Sep 14 09:53:37 CST 2017, time=2017-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412632, encodeId=7aa114126327c, content=<a href='/topic/show?id=32ec89220b' target=_blank style='color:#2F92EE;'>#HIV病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8922, encryptionId=32ec89220b, topicName=HIV病毒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fa102876871, createdName=tigerlr99, createdTime=Sat Aug 26 11:24:00 CST 2017, time=2017-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554502, encodeId=ed1a155450278, content=<a href='/topic/show?id=74e458559f5' target=_blank style='color:#2F92EE;'>#新疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58559, encryptionId=74e458559f5, topicName=新疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d03114536414, createdName=kcb074, createdTime=Sat Aug 26 11:24:00 CST 2017, time=2017-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=237221, encodeId=1b2523e2213e, content=xxlxxxl, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Sat Aug 26 06:56:10 CST 2017, time=2017-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=236879, encodeId=31aa2368e9df, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Fri Aug 25 06:58:26 CST 2017, time=2017-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=236859, encodeId=52d023685943, content=值得推荐一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLBWOEtiahpXHGVdbFId5PLgK775YNA1ria3lM9KsJT6iczgIhov5sobd1Nr0raUBP58GkUDzvfDic9RCg/0, createdBy=0d021989245, createdName=189****1577, createdTime=Fri Aug 25 06:29:48 CST 2017, time=2017-08-25, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1799648, encodeId=70b81e9964853, content=<a href='/topic/show?id=49d4e0980cc' target=_blank style='color:#2F92EE;'>#病毒耐药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70980, encryptionId=49d4e0980cc, topicName=病毒耐药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4193478, createdName=wgx306, createdTime=Tue Jan 30 19:24:00 CST 2018, time=2018-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1856055, encodeId=8f591856055fc, content=<a href='/topic/show?id=f32014428fc' target=_blank style='color:#2F92EE;'>#PNAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14428, encryptionId=f32014428fc, topicName=PNAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Sat Jul 07 09:24:00 CST 2018, time=2018-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1807578, encodeId=9424180e578a8, content=<a href='/topic/show?id=ec2b80423ef' target=_blank style='color:#2F92EE;'>#耐药问题#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80423, encryptionId=ec2b80423ef, topicName=耐药问题)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Mon Jun 25 22:24:00 CST 2018, time=2018-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958060, encodeId=6e8b195806054, content=<a href='/topic/show?id=a2cd868009b' target=_blank style='color:#2F92EE;'>#艾滋病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86800, encryptionId=a2cd868009b, topicName=艾滋病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c83329, createdName=10518093zz, createdTime=Fri Oct 13 19:24:00 CST 2017, time=2017-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=243874, encodeId=38b62438e4a8, content=学习一下很不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/23/ac01daf0962458a9eb8c0b1e2f6ce5bc.jpg, createdBy=04b81710322, createdName=1771ae4158m, createdTime=Thu Sep 14 09:53:37 CST 2017, time=2017-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412632, encodeId=7aa114126327c, content=<a href='/topic/show?id=32ec89220b' target=_blank style='color:#2F92EE;'>#HIV病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8922, encryptionId=32ec89220b, topicName=HIV病毒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fa102876871, createdName=tigerlr99, createdTime=Sat Aug 26 11:24:00 CST 2017, time=2017-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554502, encodeId=ed1a155450278, content=<a href='/topic/show?id=74e458559f5' target=_blank style='color:#2F92EE;'>#新疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58559, encryptionId=74e458559f5, topicName=新疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d03114536414, createdName=kcb074, createdTime=Sat Aug 26 11:24:00 CST 2017, time=2017-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=237221, encodeId=1b2523e2213e, content=xxlxxxl, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Sat Aug 26 06:56:10 CST 2017, time=2017-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=236879, encodeId=31aa2368e9df, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Fri Aug 25 06:58:26 CST 2017, time=2017-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=236859, encodeId=52d023685943, content=值得推荐一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLBWOEtiahpXHGVdbFId5PLgK775YNA1ria3lM9KsJT6iczgIhov5sobd1Nr0raUBP58GkUDzvfDic9RCg/0, createdBy=0d021989245, createdName=189****1577, createdTime=Fri Aug 25 06:29:48 CST 2017, time=2017-08-25, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1799648, encodeId=70b81e9964853, content=<a href='/topic/show?id=49d4e0980cc' target=_blank style='color:#2F92EE;'>#病毒耐药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70980, encryptionId=49d4e0980cc, topicName=病毒耐药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4193478, createdName=wgx306, createdTime=Tue Jan 30 19:24:00 CST 2018, time=2018-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1856055, encodeId=8f591856055fc, content=<a href='/topic/show?id=f32014428fc' target=_blank style='color:#2F92EE;'>#PNAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14428, encryptionId=f32014428fc, topicName=PNAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Sat Jul 07 09:24:00 CST 2018, time=2018-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1807578, encodeId=9424180e578a8, content=<a href='/topic/show?id=ec2b80423ef' target=_blank style='color:#2F92EE;'>#耐药问题#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80423, encryptionId=ec2b80423ef, topicName=耐药问题)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Mon Jun 25 22:24:00 CST 2018, time=2018-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958060, encodeId=6e8b195806054, content=<a href='/topic/show?id=a2cd868009b' target=_blank style='color:#2F92EE;'>#艾滋病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86800, encryptionId=a2cd868009b, topicName=艾滋病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c83329, createdName=10518093zz, createdTime=Fri Oct 13 19:24:00 CST 2017, time=2017-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=243874, encodeId=38b62438e4a8, content=学习一下很不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/23/ac01daf0962458a9eb8c0b1e2f6ce5bc.jpg, createdBy=04b81710322, createdName=1771ae4158m, createdTime=Thu Sep 14 09:53:37 CST 2017, time=2017-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412632, encodeId=7aa114126327c, content=<a href='/topic/show?id=32ec89220b' target=_blank style='color:#2F92EE;'>#HIV病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8922, encryptionId=32ec89220b, topicName=HIV病毒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fa102876871, createdName=tigerlr99, createdTime=Sat Aug 26 11:24:00 CST 2017, time=2017-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554502, encodeId=ed1a155450278, content=<a href='/topic/show?id=74e458559f5' target=_blank style='color:#2F92EE;'>#新疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58559, encryptionId=74e458559f5, topicName=新疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d03114536414, createdName=kcb074, createdTime=Sat Aug 26 11:24:00 CST 2017, time=2017-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=237221, encodeId=1b2523e2213e, content=xxlxxxl, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Sat Aug 26 06:56:10 CST 2017, time=2017-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=236879, encodeId=31aa2368e9df, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Fri Aug 25 06:58:26 CST 2017, time=2017-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=236859, encodeId=52d023685943, content=值得推荐一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLBWOEtiahpXHGVdbFId5PLgK775YNA1ria3lM9KsJT6iczgIhov5sobd1Nr0raUBP58GkUDzvfDic9RCg/0, createdBy=0d021989245, createdName=189****1577, createdTime=Fri Aug 25 06:29:48 CST 2017, time=2017-08-25, status=1, ipAttribution=)]
    2017-09-14 1771ae4158m

    学习一下很不错

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1799648, encodeId=70b81e9964853, content=<a href='/topic/show?id=49d4e0980cc' target=_blank style='color:#2F92EE;'>#病毒耐药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70980, encryptionId=49d4e0980cc, topicName=病毒耐药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4193478, createdName=wgx306, createdTime=Tue Jan 30 19:24:00 CST 2018, time=2018-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1856055, encodeId=8f591856055fc, content=<a href='/topic/show?id=f32014428fc' target=_blank style='color:#2F92EE;'>#PNAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14428, encryptionId=f32014428fc, topicName=PNAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Sat Jul 07 09:24:00 CST 2018, time=2018-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1807578, encodeId=9424180e578a8, content=<a href='/topic/show?id=ec2b80423ef' target=_blank style='color:#2F92EE;'>#耐药问题#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80423, encryptionId=ec2b80423ef, topicName=耐药问题)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Mon Jun 25 22:24:00 CST 2018, time=2018-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958060, encodeId=6e8b195806054, content=<a href='/topic/show?id=a2cd868009b' target=_blank style='color:#2F92EE;'>#艾滋病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86800, encryptionId=a2cd868009b, topicName=艾滋病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c83329, createdName=10518093zz, createdTime=Fri Oct 13 19:24:00 CST 2017, time=2017-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=243874, encodeId=38b62438e4a8, content=学习一下很不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/23/ac01daf0962458a9eb8c0b1e2f6ce5bc.jpg, createdBy=04b81710322, createdName=1771ae4158m, createdTime=Thu Sep 14 09:53:37 CST 2017, time=2017-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412632, encodeId=7aa114126327c, content=<a href='/topic/show?id=32ec89220b' target=_blank style='color:#2F92EE;'>#HIV病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8922, encryptionId=32ec89220b, topicName=HIV病毒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fa102876871, createdName=tigerlr99, createdTime=Sat Aug 26 11:24:00 CST 2017, time=2017-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554502, encodeId=ed1a155450278, content=<a href='/topic/show?id=74e458559f5' target=_blank style='color:#2F92EE;'>#新疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58559, encryptionId=74e458559f5, topicName=新疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d03114536414, createdName=kcb074, createdTime=Sat Aug 26 11:24:00 CST 2017, time=2017-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=237221, encodeId=1b2523e2213e, content=xxlxxxl, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Sat Aug 26 06:56:10 CST 2017, time=2017-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=236879, encodeId=31aa2368e9df, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Fri Aug 25 06:58:26 CST 2017, time=2017-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=236859, encodeId=52d023685943, content=值得推荐一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLBWOEtiahpXHGVdbFId5PLgK775YNA1ria3lM9KsJT6iczgIhov5sobd1Nr0raUBP58GkUDzvfDic9RCg/0, createdBy=0d021989245, createdName=189****1577, createdTime=Fri Aug 25 06:29:48 CST 2017, time=2017-08-25, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1799648, encodeId=70b81e9964853, content=<a href='/topic/show?id=49d4e0980cc' target=_blank style='color:#2F92EE;'>#病毒耐药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70980, encryptionId=49d4e0980cc, topicName=病毒耐药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4193478, createdName=wgx306, createdTime=Tue Jan 30 19:24:00 CST 2018, time=2018-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1856055, encodeId=8f591856055fc, content=<a href='/topic/show?id=f32014428fc' target=_blank style='color:#2F92EE;'>#PNAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14428, encryptionId=f32014428fc, topicName=PNAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Sat Jul 07 09:24:00 CST 2018, time=2018-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1807578, encodeId=9424180e578a8, content=<a href='/topic/show?id=ec2b80423ef' target=_blank style='color:#2F92EE;'>#耐药问题#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80423, encryptionId=ec2b80423ef, topicName=耐药问题)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Mon Jun 25 22:24:00 CST 2018, time=2018-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958060, encodeId=6e8b195806054, content=<a href='/topic/show?id=a2cd868009b' target=_blank style='color:#2F92EE;'>#艾滋病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86800, encryptionId=a2cd868009b, topicName=艾滋病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c83329, createdName=10518093zz, createdTime=Fri Oct 13 19:24:00 CST 2017, time=2017-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=243874, encodeId=38b62438e4a8, content=学习一下很不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/23/ac01daf0962458a9eb8c0b1e2f6ce5bc.jpg, createdBy=04b81710322, createdName=1771ae4158m, createdTime=Thu Sep 14 09:53:37 CST 2017, time=2017-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412632, encodeId=7aa114126327c, content=<a href='/topic/show?id=32ec89220b' target=_blank style='color:#2F92EE;'>#HIV病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8922, encryptionId=32ec89220b, topicName=HIV病毒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fa102876871, createdName=tigerlr99, createdTime=Sat Aug 26 11:24:00 CST 2017, time=2017-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554502, encodeId=ed1a155450278, content=<a href='/topic/show?id=74e458559f5' target=_blank style='color:#2F92EE;'>#新疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58559, encryptionId=74e458559f5, topicName=新疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d03114536414, createdName=kcb074, createdTime=Sat Aug 26 11:24:00 CST 2017, time=2017-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=237221, encodeId=1b2523e2213e, content=xxlxxxl, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Sat Aug 26 06:56:10 CST 2017, time=2017-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=236879, encodeId=31aa2368e9df, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Fri Aug 25 06:58:26 CST 2017, time=2017-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=236859, encodeId=52d023685943, content=值得推荐一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLBWOEtiahpXHGVdbFId5PLgK775YNA1ria3lM9KsJT6iczgIhov5sobd1Nr0raUBP58GkUDzvfDic9RCg/0, createdBy=0d021989245, createdName=189****1577, createdTime=Fri Aug 25 06:29:48 CST 2017, time=2017-08-25, status=1, ipAttribution=)]
    2017-08-26 kcb074
  8. [GetPortalCommentsPageByObjectIdResponse(id=1799648, encodeId=70b81e9964853, content=<a href='/topic/show?id=49d4e0980cc' target=_blank style='color:#2F92EE;'>#病毒耐药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70980, encryptionId=49d4e0980cc, topicName=病毒耐药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4193478, createdName=wgx306, createdTime=Tue Jan 30 19:24:00 CST 2018, time=2018-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1856055, encodeId=8f591856055fc, content=<a href='/topic/show?id=f32014428fc' target=_blank style='color:#2F92EE;'>#PNAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14428, encryptionId=f32014428fc, topicName=PNAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Sat Jul 07 09:24:00 CST 2018, time=2018-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1807578, encodeId=9424180e578a8, content=<a href='/topic/show?id=ec2b80423ef' target=_blank style='color:#2F92EE;'>#耐药问题#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80423, encryptionId=ec2b80423ef, topicName=耐药问题)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Mon Jun 25 22:24:00 CST 2018, time=2018-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958060, encodeId=6e8b195806054, content=<a href='/topic/show?id=a2cd868009b' target=_blank style='color:#2F92EE;'>#艾滋病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86800, encryptionId=a2cd868009b, topicName=艾滋病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c83329, createdName=10518093zz, createdTime=Fri Oct 13 19:24:00 CST 2017, time=2017-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=243874, encodeId=38b62438e4a8, content=学习一下很不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/23/ac01daf0962458a9eb8c0b1e2f6ce5bc.jpg, createdBy=04b81710322, createdName=1771ae4158m, createdTime=Thu Sep 14 09:53:37 CST 2017, time=2017-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412632, encodeId=7aa114126327c, content=<a href='/topic/show?id=32ec89220b' target=_blank style='color:#2F92EE;'>#HIV病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8922, encryptionId=32ec89220b, topicName=HIV病毒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fa102876871, createdName=tigerlr99, createdTime=Sat Aug 26 11:24:00 CST 2017, time=2017-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554502, encodeId=ed1a155450278, content=<a href='/topic/show?id=74e458559f5' target=_blank style='color:#2F92EE;'>#新疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58559, encryptionId=74e458559f5, topicName=新疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d03114536414, createdName=kcb074, createdTime=Sat Aug 26 11:24:00 CST 2017, time=2017-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=237221, encodeId=1b2523e2213e, content=xxlxxxl, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Sat Aug 26 06:56:10 CST 2017, time=2017-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=236879, encodeId=31aa2368e9df, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Fri Aug 25 06:58:26 CST 2017, time=2017-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=236859, encodeId=52d023685943, content=值得推荐一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLBWOEtiahpXHGVdbFId5PLgK775YNA1ria3lM9KsJT6iczgIhov5sobd1Nr0raUBP58GkUDzvfDic9RCg/0, createdBy=0d021989245, createdName=189****1577, createdTime=Fri Aug 25 06:29:48 CST 2017, time=2017-08-25, status=1, ipAttribution=)]
    2017-08-26 txqjm

    xxlxxxl

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1799648, encodeId=70b81e9964853, content=<a href='/topic/show?id=49d4e0980cc' target=_blank style='color:#2F92EE;'>#病毒耐药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70980, encryptionId=49d4e0980cc, topicName=病毒耐药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4193478, createdName=wgx306, createdTime=Tue Jan 30 19:24:00 CST 2018, time=2018-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1856055, encodeId=8f591856055fc, content=<a href='/topic/show?id=f32014428fc' target=_blank style='color:#2F92EE;'>#PNAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14428, encryptionId=f32014428fc, topicName=PNAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Sat Jul 07 09:24:00 CST 2018, time=2018-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1807578, encodeId=9424180e578a8, content=<a href='/topic/show?id=ec2b80423ef' target=_blank style='color:#2F92EE;'>#耐药问题#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80423, encryptionId=ec2b80423ef, topicName=耐药问题)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Mon Jun 25 22:24:00 CST 2018, time=2018-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958060, encodeId=6e8b195806054, content=<a href='/topic/show?id=a2cd868009b' target=_blank style='color:#2F92EE;'>#艾滋病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86800, encryptionId=a2cd868009b, topicName=艾滋病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c83329, createdName=10518093zz, createdTime=Fri Oct 13 19:24:00 CST 2017, time=2017-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=243874, encodeId=38b62438e4a8, content=学习一下很不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/23/ac01daf0962458a9eb8c0b1e2f6ce5bc.jpg, createdBy=04b81710322, createdName=1771ae4158m, createdTime=Thu Sep 14 09:53:37 CST 2017, time=2017-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412632, encodeId=7aa114126327c, content=<a href='/topic/show?id=32ec89220b' target=_blank style='color:#2F92EE;'>#HIV病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8922, encryptionId=32ec89220b, topicName=HIV病毒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fa102876871, createdName=tigerlr99, createdTime=Sat Aug 26 11:24:00 CST 2017, time=2017-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554502, encodeId=ed1a155450278, content=<a href='/topic/show?id=74e458559f5' target=_blank style='color:#2F92EE;'>#新疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58559, encryptionId=74e458559f5, topicName=新疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d03114536414, createdName=kcb074, createdTime=Sat Aug 26 11:24:00 CST 2017, time=2017-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=237221, encodeId=1b2523e2213e, content=xxlxxxl, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Sat Aug 26 06:56:10 CST 2017, time=2017-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=236879, encodeId=31aa2368e9df, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Fri Aug 25 06:58:26 CST 2017, time=2017-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=236859, encodeId=52d023685943, content=值得推荐一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLBWOEtiahpXHGVdbFId5PLgK775YNA1ria3lM9KsJT6iczgIhov5sobd1Nr0raUBP58GkUDzvfDic9RCg/0, createdBy=0d021989245, createdName=189****1577, createdTime=Fri Aug 25 06:29:48 CST 2017, time=2017-08-25, status=1, ipAttribution=)]
    2017-08-25 龙胆草

    学习谢谢分享

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=1799648, encodeId=70b81e9964853, content=<a href='/topic/show?id=49d4e0980cc' target=_blank style='color:#2F92EE;'>#病毒耐药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70980, encryptionId=49d4e0980cc, topicName=病毒耐药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4193478, createdName=wgx306, createdTime=Tue Jan 30 19:24:00 CST 2018, time=2018-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1856055, encodeId=8f591856055fc, content=<a href='/topic/show?id=f32014428fc' target=_blank style='color:#2F92EE;'>#PNAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14428, encryptionId=f32014428fc, topicName=PNAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Sat Jul 07 09:24:00 CST 2018, time=2018-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1807578, encodeId=9424180e578a8, content=<a href='/topic/show?id=ec2b80423ef' target=_blank style='color:#2F92EE;'>#耐药问题#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80423, encryptionId=ec2b80423ef, topicName=耐药问题)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Mon Jun 25 22:24:00 CST 2018, time=2018-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958060, encodeId=6e8b195806054, content=<a href='/topic/show?id=a2cd868009b' target=_blank style='color:#2F92EE;'>#艾滋病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86800, encryptionId=a2cd868009b, topicName=艾滋病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c83329, createdName=10518093zz, createdTime=Fri Oct 13 19:24:00 CST 2017, time=2017-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=243874, encodeId=38b62438e4a8, content=学习一下很不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/23/ac01daf0962458a9eb8c0b1e2f6ce5bc.jpg, createdBy=04b81710322, createdName=1771ae4158m, createdTime=Thu Sep 14 09:53:37 CST 2017, time=2017-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412632, encodeId=7aa114126327c, content=<a href='/topic/show?id=32ec89220b' target=_blank style='color:#2F92EE;'>#HIV病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8922, encryptionId=32ec89220b, topicName=HIV病毒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fa102876871, createdName=tigerlr99, createdTime=Sat Aug 26 11:24:00 CST 2017, time=2017-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554502, encodeId=ed1a155450278, content=<a href='/topic/show?id=74e458559f5' target=_blank style='color:#2F92EE;'>#新疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58559, encryptionId=74e458559f5, topicName=新疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d03114536414, createdName=kcb074, createdTime=Sat Aug 26 11:24:00 CST 2017, time=2017-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=237221, encodeId=1b2523e2213e, content=xxlxxxl, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Sat Aug 26 06:56:10 CST 2017, time=2017-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=236879, encodeId=31aa2368e9df, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Fri Aug 25 06:58:26 CST 2017, time=2017-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=236859, encodeId=52d023685943, content=值得推荐一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLBWOEtiahpXHGVdbFId5PLgK775YNA1ria3lM9KsJT6iczgIhov5sobd1Nr0raUBP58GkUDzvfDic9RCg/0, createdBy=0d021989245, createdName=189****1577, createdTime=Fri Aug 25 06:29:48 CST 2017, time=2017-08-25, status=1, ipAttribution=)]
    2017-08-25 189****1577

    值得推荐一下

    0

相关资讯

PLoS Pathog:研究解密艾滋病早期感染机制,或将彻底终结这一疾病!

艾滋病的感染过程究竟是怎样的呢?目前来自东京大学的研究人员解开了病毒初始阶段的传播过程。当病毒进入细胞时,在第一个步骤的过程中,它会感染细胞的蛋白质外衣,这也是围绕着病毒的遗传物质。病毒可以培养自己的DNA基因,将其插入到细胞的基因组。这就可以使病毒劫持宿主细胞,迫使细胞复制的病毒。

艾滋病三合一复方新药获批在中国上市

近日,国家食品药品监督管理总局(CFDA)批准了艾滋病治疗新复方制剂绥美凯(化学名:多替阿巴拉米片)进入中国。绥美凯作为具有明显临床治疗优势的创新性单片复方制剂,能够为艾滋病患者治疗提供极大的便利性,获得国家食药监总局的优先审评审批。

(警惕)这里艾滋病感染人数破700万大关

南非统计局7月31日发布了最新的人口统计数据。统计显示,南非的艾滋病感染者人数已经达到706万,比去年增加了13万。同时,南非的艾滋病感染率也创下了新高,增长到12.57%。

广东7月份新增艾滋病433例,因艾滋病死亡71人

广东卫计委11日发布该省7月份传染病疫情报告,报告显示,7月份广东共报告新增艾滋病例433例,因艾滋病死亡71人。7月份广东全省共报告甲、乙类传染病发病39251例,死亡94人。其中,无报告甲类传染病。乙类除传染性非典型肺炎、脊髓灰质炎、人感染高致病性禽流感、炭疽、白喉、血吸虫病、H7N9无发病、死亡报告外,其余19种传染病均有发病报告。7月广东的乙类传染病报告发病数居前五位的病种分别为乙肝、肺结

艾滋病“功能性治愈”再现曙光

南非一名被艾滋病病毒(HIV)感染的儿童正在不使用抗逆转录病毒药物(ARV)的情况下控制病毒。这重新推动了寻找方法使人们无须治疗便能长期控制病毒的努力。

不实报道使人空欢喜 攻克艾滋病道阻且长

相信在众多传染病中,艾滋病是最难治愈的疾病之一。它对人体的免疫力具有极强的破坏力,潜伏期后患者常常受到多种感染的折磨。正因为艾滋病的传染性、难治愈、预后差等特征,往往与艾滋病有关的研究和突破更能吸引人们的注意。近日,“马赛克”疫苗的报道被媒体疯狂转载,然而经证实,报道中很多成分言过其实。那么真相到底是怎样的呢?